Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following conferences taking place in February:
Leerink Partners 6th Annual Global Healthcare Conference, at the Lotte New York Palace Hotel in New York City
- Matthew Kapusta, chief executive officer, will participate in a Fireside Chat on Wednesday, February 15th at 3.00 p.m. EST. The live webcast can be accessed by the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/overview.php. The webcast replay will be available for at least 72 hours following the live event.
61st Annual Meeting of Society of Thrombosis and Hemostatis Research at the Congress Center in Basel, Switzerland
- Professor Wolfgang Miesbach, M.D. professor of hematology at the University of Frankfurt, Germany and an investigator in the ongoing Phase 1-2 clinical trial of AMT-060 (AAV5 hFIX) gene transfer in adult patients with severe hemophilia B, will present previously disclosed interim results from the dose escalating study on Thursday, February 16th at 15.00 CET/ 09.00 a.m. EST.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
